Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V116 in Adults 18-64 at Increased Risk for Pneumococcal Disease (STRIDE-8)
NCT05696080Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2023
- Primary completion
- Feb 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 8
01
Overview
A Phase 3 trial of pneumococcal 21-valent conjugate vaccine in pneumococcal infection, sponsored by Merck & Co.. Started Feb 2023; status: completed.
02
Drugs
pneumococcal 21-valent conjugate vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT05696080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05696080.